Palbociclib (PD-0332991) is a selective CDK4/6 inhibitor approved for use in combination with letrozole to treat hormone receptor-positive advanced breast cancer as initial endocrine therapy (66). This evidence concerns the gene CDK4 and breast carcinoma.